Navigation Links
GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
Date:10/26/2011

EDINBURGH, Scotland, Oct. 26, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis.

The alliance will build on work by university researchers that recently uncovered a molecular mechanism believed to have a major role in triggering life-threatening multiple organ failure. The collaboration will integrate the deep biology and disease understanding of the academic group led by Damian Mole and Dr. Scott Webster of the University's College of Medicine and Veterinary Medicine with GSK's expertise in drug discovery and development.

"Despite treatment for severe acute pancreatitis, up to a quarter of people affected will die from an attack. By teaming up with GSK, we have the opportunity to turn our science into a medicine," said Mole. Webster added, "This is a great example of translating academic research. The alliance brings together our collective expertise in target biology and drug discovery to tackle an enormous unmet medical need."

Work on the project will be carried out both within GSK and at the College of Medicine and Veterinary Medicine located at the Edinburgh BioQuarter (http://bit.ly/tfrXA7), Scotland's flagship life sciences development.

Under the terms negotiated by the BioQuarter, the University will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration.

This alliance comes through GSK's Discovery Partnerships with Academia (DPAc) team, a recently formed group designed to bring together the complementary skill sets of GSK and individual academic groups in the search for innovative medicines.

Dr. Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: "This collaborative partnership with a world-leader in drug discovery demonstrates the strength and depth of research being conducted here in Edinburgh. We are delighted to have been selected as one of just ten DPAc projects being awarded globally by GlaxoSmithKline."

About Edinburgh BioQuarter

At the heart of Scottish life sciences, Edinburgh BioQuarter is a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise. Edinburgh BioQuarter commercializes world-leading medical research and brings investors, ideas and companies together at the BioQuarter campus on the outskirts of Edinburgh. For more information, visit www.edinburghbioquarter.com.


'/>"/>
SOURCE Edinburgh BioQuarter
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ian Tomlinson Joins SBC Board as GlaxoSmithKline Representative Director
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
6. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
7. GlaxoSmithKline Completes Acquisition of Stiefel
8. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
9. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. GlaxoSmithKline Reports Q4 and Year End Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... ... 2016 , ... A new study published in the just-published ... advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue ... sampling may improve the value of a blood-based test.” The study was conducted ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):